Soligenix Reports Q1 2025 Financial Results and Milestones

Soligenix Inc ( (SNGX) ) has released its Q1 earnings. Here is a breakdown of the information Soligenix Inc presented to its investors.

Soligenix, Inc. is a late-stage biopharmaceutical company that focuses on developing and commercializing products for rare diseases with unmet medical needs, operating primarily in the biopharmaceutical sector.

In its recent earnings report for the first quarter of 2025, Soligenix highlighted several strategic milestones and financial results. The company is advancing its clinical programs, with significant development milestones anticipated, including top-line results from ongoing studies in cutaneous T-cell lymphoma, Behçet’s disease, and psoriasis.

The company reported no revenue for the quarter, a decrease from the previous year’s $0.1 million, primarily due to a reduction in grant-related revenue. Soligenix’s net loss increased to $3.2 million from $1.9 million in the same quarter last year, driven by higher operating expenses related to clinical trials and a decrease in other income. Research and development expenses rose to $2.2 million, reflecting ongoing clinical studies and manufacturing costs, while general and administrative expenses saw a slight increase to $1.1 million.

Looking ahead, Soligenix remains committed to its strategic goals, with a cash position of approximately $7.3 million expected to sustain operations through the end of 2025. The company continues to explore strategic options, including partnerships and potential financing opportunities, to support its late-stage pipeline and future growth.